卡培他滨联合奥沙利铂治疗进展期胃癌68例

目的：观察卡培他滨联合奥沙利铂治疗进展期胃癌的疗效及安全性。方法：经病理证实的进展期胃癌患者，应用卡培他滨2000mg／m^2，分早晚2次口服，d1-d14，服用2周后休息1周；奥沙利铂130mg／m^2，静脉滴注，持续4h以上，d1，21天为1个周期。结果：全组68例患者，获CR2例，PR34例，总有效率为52．9％，中位疾病进展时间（TTP）为7．3个月。中位生存期（OS）11．9个月。1年生存率为42．9％。毒副反应以Ⅰ～Ⅱ度为主，出现Ⅲ度白细胞减少3例、血小板减少5例、恶心呕吐1例以及腹泻4例，无Ⅳ度毒副反应。结论：卡培他滨联合奥沙利铂治疗进展期胃癌有效率较高，毒副反应较低，患者耐受性好。

Clinical observation of capecitabine plus oxaliplatin in treatment of advanced gastric cancer

Objective：To evaluate the response rate, time to progression, overall survival, and safety of the combination of capecitabine plus oxaliplatin in the treatment of advanced gastric cancer. Methods：Previously untreated patients with advanced gastric cancer were treated with combination of capecitabine （2 000 mg/m^2 twice daily, days 1-14） plus oxaliplatin （130 mg/m^2 as a 4 h intravenous infusion on day 1 ） every 3 weeks. Results ： All 68 patients were received the treatlnent. Two cases of complete response （CR） and 34 cases of partial response （PR） were confirmed, giving an overall response rate of 52. 9% （95% CI, 41.0-64. 8% ）. The median time to progression （TIP） and overall survival for all patients were 7.3 months （95% CI, 6. 0-8. 6 months） and 11.9 months （95% CI, 9.4-14. 4 months）. Grade 3 leukopenia, thrombocytopenia, nausea/vomiting, and diarrhea were observed in 3, 5, 1, and 4 patients, respectively. No grade 4 toxicity was observed. Conclusion： Capecitabine plus oxaliplatin combination chemotherapy is active in patients with previously untreated advanced gastric cancer.